P
ITUITARY CELL COMMITMENT and terminal differentiation follows a well-orchestrated temporal and spatial developmental cascade arising from multipotential cells (1) (2) (3) (4) . The mature gland comprises at least five highly differentiated hormone-secreting cell types.
Pituitary tumors develop due to intrinsic adenohypophysial cell alterations or altered growth factor availability (5, 6) . Mutations in three genes have been linked to a familial predisposition to development of human pituitary tumors including multiple endocrine neoplasia type I (7), gsp (8) , and PRKAR1a (9) . Disrupted cell cycle regulatory genes, including Rb, p27, and p18, also result in murine pituitary tumor development, mainly in the intermediate lobe (10) (11) (12) .
Pituitary tumor-transforming gene (PTTG), isolated by differential display from GH-secreting pituitary tumor cell lines (13) , is expressed in actively proliferating normal tissue especially the testis and lymphopoietic system, and in several tumor types (13) (14) (15) (16) (17) (18) (19) (20) . PTTG is required for tissue self-renewal and pttg-null mice have hypoplastic testes, spleen, and pituitary glands (21) . Male pttg-null mice also develop diabetes due to decreased pancreatic ␤-cell mass and proliferation (22) .
PTTG acts as a securin protein essential for mitosis (23) . During the cell cycle, a complex series of events ensures timely and equal separation of sister chromatids. During metaphase, sister chromatids are bound by cohesin, which is degraded by separin leading to chromatid separation at anaphase. PTTG binds separin and blocks chromatid separation at metaphase. Separase activation occurs upon PTTG degradation by the anaphase-promoting complex at the metaphase-anaphase transition. Thus, too much or too little PTTG results in chromosomal instability and aneuploidy (21, (24) (25) (26) .
Several lines of evidence support the role of PTTG in tumorigenesis. Overexpressed PTTG induces cell aneuploidy (24) , transforms NIH3T3 cells in vitro and in vivo (13) , stimulates fibroblast growth factor production (6, 14, 20) , and induces angiogenesis (5) . Of genes associated with malignant cell behavior, PTTG was identified as one of nine genes comprising the "expression signature" for metastatic potential of solid tumors (27) . Expression of a dominant-negative PTTG motif blocks experimental rat pituitary adenoma growth (28), whereas PTTG deletion protects Rbϩ/Ϫ mice from developing pituitary and thyroid tumors (29) .
These observations underscore the requirement of PTTG for pituitary tumorigenesis.
Pituitary cell differentiation and commitment follow a well-orchestrated temporal and spatial cascade arising from multipotential stem cells. Temporal and spatial expression of transcription factors and growth factors determine the specificity of hormone-secreting cell commitment. For example, Prop-1 determines specific GH, prolactin, and TSH expression (1), T-Pit is required for proopiomelanocortin gene expression (1, 30) , and steroidogenic factor 1 is required for gonadotroph cell commitment (31) . The dimeric glycoprotein hormones, FSH, LH, and TSH, are comprised of a common ␣-subunit [␣-subunit of glycoprotein hormone (␣GSU)] and a specific ␤-subunit. As ␣GSU is the earliest expressed pituitary hormone gene product (32) , transgenic mice were generated with the ␣GSU promoter driving PTTG expression, to determine the impact of early pituitary PTTG expression. The results showing development of multihormonal tumors, by allowing hyperproliferation of early ␣GSU-expressing cells, lend credence to the presence of a multipotential early anterior pituitary stem cell.
RESULTS

Targeted Pituitary Human (h) PTTG1 Expression in Transgenic Mice
To gain further insight into the in vivo requirement of PTTG for pituitary cell proliferation, transgenic mice expressing ␣GSU-directed hPTTG1 cDNA and enhanced green fluorescent protein (EGFP) were generated (Fig. 1A) . Of four founder lines (three males and one female), one male founder failed to reproduce and developed intermediate lobe hyperplasia at 4 months of age, one was subfertile and gave rise to transgenic animals that failed to reproduce due to reproductive tract pathologies, and one sired transgenic offspring with a variety of phenotypes. Female transgenic mice were fertile and appeared healthy, and many offspring were obtained from the one female founder (Table 1) . Female mice had enlarged pituitaries with elevated levels of serum IGF-I (␣GSU.PTTG: 637 Ϯ 135 vs. wild type: 250 Ϯ 60 ng/ml; P Ͻ 0.05). A greater increase in pituitary size in response to pregnancy and lactation was also observed in transgenic females, as assessed by magnetic resonance imaging (MRI) (data not shown).
A summary of ␣GSU.PTTG phenotypes is shown in Table 2 . There was a nonsignificant increase in body weight in ␣GSU.PTTG mice, and some male transgenic mice died prematurely at 8-12 months of age as a result of urinary tract obstruction and inflammation. MRI of male transgenic animals demonstrated larger and irregularly shaped pituitary glands than wild type (Fig. 2) . Pituitary transgene expression was confirmed by demonstrating EGFP expression using scanning confocal microscopy. The EGFP signal was visualized on both the pituitary surface and up to 100 m deep. Transgenic, but not wild-type, pituitary glands expressed EGFP in cell clusters assembled in two bilateral streaks in some animals (Fig. 3A) . Rows of EGFPpositive cells juxtaposed to blood vessels were evident, and PTTG immunostaining showed focal PTTG expression (Fig. 3B ). Focal PTTG expression was accompanied by loss of the reticulin network in some animals (Fig. 3E) , indicating microadenoma rather than hyperplasia. Figure 3 , C-F, depicts an example of a microadenoma coexpressing LH and PTTG, with vacuolizations.
Because the mouse ␣GSU promoter targets transgene expression to both gonadotropes and thyrotropes (32), double-label immunocytochemistry was performed to determine hormonal PTTG coexpres- Fig. 1 . Generation of ␣GSU.PTTG Transgenic Mice A, ␣GSU.PTTG transgene construct consisting of the ␣GSU promoter driving expression of hPTTG1 and EGFP. IRES sequences allow for expression of both hPTTG1 and EGFP proteins. B, Mouse genotyping using Southern blot analysis. Tail DNA was digested with EcoRI and resolved on a 1.0% agarose gel. After transfer, the membrane was hybridized with a randomradiolabeled probe comprising the 1.2-kb XbaI fragment containing part of the bridging ␣GSU promoter and PTTG junction. Expected size of the transgenic fragment is 6.8 kb (arrow). P, Injected plasmid with vector digested with EcoRI as control; WT, wild type; TG, transgenic; IRES, internal ribosome entry site.
sion. Control pituitary glands derived from wild-type littermates did not exhibit appreciable PTTG immunofluorescence, but transgenic pituitaries expressed PTTG immunoreactivity in most, but not all, ␣GSU-expressing cells. Figure 4 , A and B show ␣GSU staining using fluorescein-labeled antibodies (green) and PTTG staining with Texas Red (red). Double-labeled cells are yellow. PTTG was expressed in some, but not all, ␣GSU cells as well as other cell types. Because LH and TSH are coexpressed with ␣GSU, pituitary sections were costained for LH (Fig. 4D) , TSH ( Fig. 4E) , and PTTG. PTTG was expressed in both LH and TSH. Surprisingly, non-␣GSU cells that expressed PTTG also costained for GH (Fig. 4C) , and some GH cells expressed ␣GSU (Fig. 4F ). Focal expansion of ␣GSU, LH, and/or GH cells was observed in some animals ( Fig. 5 ), whereas expression of pituitary ACTH and prolactin was normal (data not shown).
Pathological findings in transgenic pituitaries consisted of microscopic focal expansion of hormonespecific cells with ribbon-like pattern of tumor cells and vacuolizations. Exclusion of other immunoreactive hormones from these areas was indicative of cell specificity. Loss of reticulin network was also a hallmark of adenomatous change. Large macroscopic adenomas were not observed, likely because animals died early from renal tract obstruction.
Shown in Fig. 5 are two representative male transgenic pituitaries; one with a plurihormonal focal adenoma consisting of ribbon-like PTTG-expressing cells that costained for ␣GSU, LH, TSH, and GH ( Table 2 depicts serum hormone levels observed in wild-type and transgenic mice. FSH, TSH, and T 4 levels were not different in male transgenic from wildtype mice (Table 2) . LH and GH levels were elevated in some, but not all, transgenic animals ( Table 2 and Fig. 6, A and B). However, mean serum testosterone and IGF-I levels were higher in transgenic than in wild-type mice (Table 2 and Fig. 6 , C and D), as were testicular testosterone levels (data not shown).
Hormone Levels
Male Genitourinary Tract Pathology
The most striking phenotype observed in ␣GSU.PTTG male transgenic mice was that of urinary tract obstruction secondary to prostate hyperplasia evident at 8-12 months of age. The urinary bladder was enlarged with wall thickening and filled with urine containing inflammatory cells and white deposits. Seminal vesicles were also enlarged ( Fig. 7 ), but testicular weight was unchanged. Seminal vesicle histology showed fibromuscular stromal thickening with signs of inflammation or adenoma in some animals (Fig. 7) . Histological examination of the prostate revealed focal micropapillary hyperplasia with dilated ducts, cell atypia, and prostate intraepithelial neoplasia. It is characterized by multifocal proliferative regions of atypical epithelial cells in multiple ductules with cribriform and/or tufting growth patterns with progressive nuclear atypia. These patterns appear as bridges of epithelial cells within each ductule. In some animals that died prematurely, stromal hyperplasia, and inflammatory prostatitis were observed (Fig. 8) .
DISCUSSION
Targeted expression of PTTG using the mouse ␣GSU promoter results in focal PTTG expression in LH-and GH-producing cells ranging from hyperplasia to frank adenoma development. The finding of GH cell hyperplasia was surprising because the ␣GSU promoter has not been shown to drive expression to mature somatotrope cells. Increased GH and LH result in elevated IGF-I and testosterone levels, respectively, resulting in marked prostate and seminal vesicle neoplasia. Prostate hyperplasia results in bladder obstruction, kidney reflex, and inflammation. Some phenotypic features of ␣GSU.PTTG male mice are reminiscent of previously reported defects in mice that overexpress human chorionic gonadotropin (35, 36) , suggesting a role for LH overexpression in the pathogenesis of prostate hyperplasia. These observations suggest that PTTG overexpression in the developing pituitary targets early pituitary multipotential cells or, alternatively, may influence neighboring non-␣GSU-expressing cells by a paracrine mechanism. How is transgene expression in GH cells explained? The mouse ␣GSU promoter targets PTTG expression to pituitary stem cells early in development, with the potential to give rise to all pituitary hormone cell types. Nevertheless, mature somatotrope cells rarely express ␣GSU. However, Camper and co-workers (37) labeled early embryonic cells with ␤-galactosidase and showed that all pituitary cells, including GH cells, appear to originate from ␣GSU progenitor cells. Nevertheless, why PTTG is not suppressed in GH cells remains to be determined. Some GH cells express ␣GSU modestly (38) , as do GH-secreting tumor cells (39, 40) , supporting the hypothesis for a common plastic pituitary precursor lineage. Overexpressed thyrotrope PTTG may have resulted in thyrotrope hyperplasia and transdifferentiation of these cells into somatotropes, because these cells share the common Pit-1 lineage. Transdifferentiation of GH-secreting from TSH-secreting cells has been reported in states of hypothyroidism leading to TSH hyperplasia (41) . Gonadotrope PTTG overexpression may also result in paracrine regulation of GH cell proliferation. For example, female transgenic mice that hypersecrete LH also exhibit elevated serum GH levels (42, 43) .
Recent observations have suggested that a subpopulation of embryonic pituitary cells may coexpress two or more hormone mRNAs. ␣GSU with GH and/or prolactin expression are the earliest coexpressed hormones occurring at embryonic d 16. Age-related changes in combined single-cell hormone coexpression did not correspond with those observed for single hormone expression, suggesting a unique response of coexpressing adenohypophysial cells to developmental signals (38) . The results shown here, whereby ␣GSU-driven PTTG gives rise to adenomas of both glycoprotein hormones as well as GH-secreting cells, provide further evidence for the coexpression of ␣GSU in embryonic somatotropes.
Prostate, seminal vesicle, and urinary tract pathology is attributed to increased pituitary secretion of both LH and GH, resulting in elevated testosterone and IGF-I levels, respectively. Although high levels of all four hormones were rarely observed in the same animal, most ␣GSU.PTTG male mice had abnormally elevated levels of at least one of these hormones. Not surprisingly, these animals developed prostate pathology as both testosterone (44) and IGF-I (45-49) have been linked to prostate hyperplasia and tumors. As the animals aged, prostate enlargement resulted in urinary tract obstruction leading to urinary bladder enlargement, inflammation, and even pyelonephritis in some animals.
These studies suggest that early overexpressed PTTG results in proliferation of multihormonal pituitary cells, underscoring the role of PTTG in pituitary cell proliferation and adenoma formation, and also point to the presence of a multipotential early pituitary stem cell expressing ␣GSU. Cell vacuolization is a hallmark of acidophilic stem cell adenoma. The large clear vacuoles observed in acidophilic stem cell adenoma are due to mitochondrial accumulation that can be seen as a giant mitochondrion under electron microscopy, which is indicative of oncocytic change (34) . Previous studies have shown that PTTG abundance is increased in several tumor types, and its overexpression results in cell transformation. Our results validate that in vivo overexpression of PTTG itself induces abnormal pituitary cell proliferation and adenomas. Potential mechanisms include induction of aneuploidy as a result of dysregulation of sister chromatid separation (24, 50) , regulation of other cell cycle proteins, including p53 (51, 52) , or transactivation with other transcription factors involved in pituitary proliferation (19, 53) .
MATERIALS AND METHODS
DNA Constructs
The hPTTG1-IRES2-EGFP plasmid was constructed by replacement of PCMV by the 4.6 kb (KpnI-HindIII) fragment of the rat ␣GSU promoter region [generously provided by Dr. E. C. Ridgway (32)], and by insertion of a 654-bp (Xho I-MluI) fragment containing the full-length hPTTG1 cDNA into the polylinker region of the pIRES2-EGFP vector (CLONTECH Laboratories, Inc., Palo Alto, CA) with the following restriction sites replaced by linkers: AseI by SacII and AflII by SfiI, respectively (Fig. 1A) .
Transgenic Mice
hPTTG1-IRES2-EGFP was digested with KpnI and AflII, the transgene was microinjected into B6C3-fertilized mouse pronuclei, and injected eggs were transplanted to pseudopregnant foster mothers at the University of California Los Angeles Transgenic Core Facility. For genotyping, either Southern blots or PCR using EGFP primers (AGAACGGCATCAAGGT-GAAC and CAGAAGAACGGCATCAAGGT) were performed. All animal experiments were performed according to the guidelines of the Institutional Animal Care and Use Committee. Briefly, mice were housed in microisolator cages and cubicles in a room with 12-h light, 12-h dark cycle. Animals were euthanized using CO 2 chambers, and blood was withdrawn directly from the heart. Pituitary glands were collected and fixed in 2% paraformaldehyde for 2 h whereas remaining organs were fixed in formalin.
Southern Blots
Tail genomic DNA samples were digested with EcoRI and resolved on 1% agarose gel. After DNA transfer to Hybond-n ϩ (Amersham Pharmacia Biotech, Arlington Heights, IL) membrane, it was hybridized with a radiolabeled probe comprising a 1.2-kb XbaI fragment containing the junction of the ␣GSU promoter and hPTTG1 (Fig. 1B) . Upon exposure of the membrane to film, a 6.8-kb band appears in transgenic samples. Injected plasmid DNA digested with EcoRI was used as control.
Confocal Microscopy
Scanning confocal images were obtained using a confocal microscope TCS-SP confocal scanner (Leica Microsystems, Mannheim, Germany). Images were taken with a ϫ10, 0.3 N.A. Plan Fluotar. The objective provides a scan field of 1 ϫ 1 mm. Because the pituitary is significantly larger, we performed a tiled scan. The complete imaging field was divided into three ϫ four quadrants. Each quadrant was scanned separately as a 200-m deep stack with 7-m spaced optical sections along the z-axis. The sample was positioned by a Scan motorized stage (Mä rzhä user, Wertzlar, Germany), maximum intensity projection was calculated for each stack, and aligned projections were assembled into the final figure. The spectrophotometer was set to optimal EGFP detection to a wide setting of 500-590 nm. Pinhole was set to 1.5 Airy units to provide for depth penetration and efficient light collection.
Histology
Tissue sectioning was performed by the Department of Pathology at Cedars Sinai Medical Center. For the pituitary, 4-m sections of paraformaldehyde-(2% in PBS for 2 h) fixed and paraffin-embedded tissue were obtained and stained for hematoxylin and eosin or reticulin silver stain. Double-labeled immunocytochemistry was performed using a previously optimized protocol (42, 43) . Secondary antibodies included fluorescein thiocyanate-labeled antirabbit, Cy3-labeled antirabbit, Rhodamine-labeled antirabbit, and fluorescein thiocyanate-labeled antiguinea pig. When the Envision kit was used, secondary antibodies and chromagens were used according to manufacturer specification. For PTTG immunostaining, an antigen-retrieval step was performed before incubation with primary antibody. Slides were counterstained with 4Ј,6-diamidino-2-phenylindole or hematoxylin to visualize nuclei. 
RIA
Serum IGF-I was measured using the rat IGF-I RIA kit (DSL, Inc., Webster, TX). A solid-phase RIA for measurement of total testosterone (Coat-A-Count, Diagnostic Products Corp., Los Angeles, CA) in diethyl ether extracted serum samples. The DPC Coat-A-Count total T 4 assay was also used. For GH measurements, a rat GH RIA was used as previously described (54) . LH and FSH levels were assayed by the University of Virginia Center for Cellular and Molecular studies in Reproduction.
MRI
We used a clinical whole-body 1.5 Tesla MRI system (Siemens Visions, Madison, WI) to image the mouse pituitary. Procedures were performed during nonclinical hours between 2100 h and 0700 h, and equipment was disinfected before and after animal imaging. Animals were anesthetized with avertin and imaged using a small solenoidal receiver coil. We obtained T1-weighted spin echo images (repetition time, 400 msec; echo time, 14 msec; number of signal averages, 4; imaging time, 6 min, 53 sec; slice thickness, 1 mm; in-plane resolution, 195 m) in the coronal and sagittal imaging planes. Pituitary volume was determined by multiplying pixel volume by the number of pixels within the pituitary gland as defined by a region of interest that was manually drawn on magnified sagittal images using the MRI system console. 
Statistical Analysis
Because most comparisons were made between wild-type and transgenic littermates, an unpaired Student's t test was used to determine statistical significances, which are determined at P Ͻ 0.05.
